Reverse transformation of Modic Type 2 changes to Modic Type 1 changes during sustained chronic low-back pain severity

2007 ◽  
Vol 6 (2) ◽  
pp. 152-155 ◽  
Author(s):  
Laurence A. G. Marshman ◽  
Matthew Trewhella ◽  
Tai Friesem ◽  
Chandra K. Bhatia ◽  
Manoj Krishna

✓Modic Type 2 (MT2) neuroimaging changes are considered stable or invariant over time and relatively quiescent, whereas Modic Type 1 (MT1) changes are considered unstable and more symptomatic. The authors report two cases in which MT2 changes were symptomatic and evidently unstable, and in which chronic low-back pain severity remained unaltered despite a MT2–MT1 reverse transformation. Two women (41 and 48 years old) both presented with chronic low-back pain. Magnetic resonance (MR) images demonstrated degenerating discs at L5–S1 associated with well-established MT2 changes in adjacent vertebrae. Repeated MR imaging in these two patients after 11 months and 7 years, respectively, revealed reverse transformation of the MT2 changes into more florid MT1 changes, despite unaltered chronic low-back pain severity. Following anterior discectomy and disc arthroplasty, immediate abolition of chronic low-back pain was achieved in both patients and sustained at 3-year follow up. Modic Type 2 changes are therefore neither as stable nor as quiescent as originally believed. Each type can change, with equal symptom-generating capacity. More representative imaging–pathological correlates are required to determine the precise nature of MT changes.

2019 ◽  
Vol 62 (1) ◽  
pp. 3-7 ◽  
Author(s):  
Laura Boutevillain ◽  
Armand Bonnin ◽  
Aurore Chabaud ◽  
Claire Morel ◽  
Mathias Giustiniani ◽  
...  

2019 ◽  
Vol 86 (1) ◽  
pp. 109-110
Author(s):  
A. Amouzougan ◽  
K. Boussoualim ◽  
H. Marotte ◽  
F.G. Barral ◽  
T. Thomas

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Elisabeth Gjefsen ◽  
Lars Christian Haugli Bråten ◽  
Guro Løvik Goll ◽  
Monica Wigemyr ◽  
Nils Bolstad ◽  
...  

Abstract Background Low back pain is common and a significant number of patients experience chronic low back pain. Current treatment options offer small to moderate effects. Patients with vertebral bone marrow lesions visualized as Modic changes on magnetic resonance imaging may represent a subgroup within the low back pain population. There is evidence for inflammatory mediators being involved in development of Modic changes; hence, suppression of inflammation could be a treatment strategy for these patients. This study examines the effect of anti-inflammatory treatment with the TNF-α inhibitor infliximab in patients with chronic low back pain and Modic changes. Methods/design The BackToBasic trial is a multicenter, double blind, randomized controlled trial conducted at six hospitals in Norway, comparing intravenous infusions with infliximab with placebo. One hundred twenty-six patients aged 18–65 with chronic low back pain and type 1 Modic changes will be recruited from secondary care outpatients’ clinics. The primary outcome is back pain-specific disability at day 154 (5 months). The study is designed to detect a difference in change of 10 (SD 18) in the Oswestry Disability Index at day 154/ 5 months. The study also aims to refine MRI-assessment, investigate safety and cost-effectiveness and explore the underlying biological mechanisms of Modic changes. Discussion Finding treatments that target underlying mechanisms could pose new treatment options for patients with low back pain. Suppression of inflammation could be a treatment strategy for patients with low back pain and Modic changes. This paper presents the design of the BackToBasic study, where we will assess the effect of an anti-inflammatory treatment versus placebo in patients with chronic low back pain and type 1 Modic changes. The study is registered at ClinicalTrials.gov under the identifier NCT03704363. The EudraCT Number: 2017–004861-29.


Sign in / Sign up

Export Citation Format

Share Document